– Securing additional research capabilities to accelerate growth in the biosolutions sector
– Laboratory and technology development center of approximately 1,500 m2 , office space of 700 m2 – Optimal conditions for the central research campus in Munich
-We plan to focus on research into future biopharmaceutical manufacturing processes and food and health supplement raw materials.
Global chemical and biotechnology company Wacker Chemie AG has officially opened the WACKER Biotechnology Center in Munich. The opening ceremony was attended by key figures from politics, business, and academia in Europe, and Wacker has invested tens of millions of euros in this new facility.
Christian Hartel, CEO of Wacker Chemicals, said at the opening ceremony: “The Wacker Biotechnology Center will play a key role in centralizing and strengthening our bio-research activities. We see enormous growth potential in this area, which is why we have made the bold investment, even in difficult economic times.”
Hubert Aiwanger, Bavarian Minister of Economic Affairs, also said: “The opening of this center will not only create quality jobs, but will also contribute to further enhancing Bavaria’s biotechnology capabilities. With this investment, Wacker Chemicals will strengthen its position as a leading innovative company in Bavaria and is a very desirable example of increasing regional competitiveness.”
The newly opened Biotechnology Center is located on Wacker Chemicals’ main R&D site in Munich’s Sendling Campus, where the company has been conducting basic research for over 100 years and bio-related research since the 1980s.
As the bio business expanded and existing research space reached its limits, Barker Chemicals opened a new technology center with state-of-the-art infrastructure that can accommodate around 90 researchers.
It consists of a total of 4 floors, a laboratory and technology development center of approximately 1,500㎡, and an office space of 700㎡. Research is focused on the production technology of protein and nucleic acid-based active substances, including the manufacturing process of next-generation pharmaceuticals, biopharmaceuticals. Proteins and nucleic acids are important materials for developing groundbreaking treatments using active ingredients based on messenger ribonucleic acid (mRNA). In addition, the development of innovative raw materials for functional foods and health functional foods is also included as a major research area, which will contribute to the development of healthy and sustainable nutritional solutions for today and future generations.
By consolidating its bio-research capabilities in one space, Wacker Chemicals is focusing on maximizing research efficiency and shortening the time from R&D to actual product launch. CEO Christian Hartel emphasized, “It is no longer enough to simply have the best solution. Being the first to provide a solution to the customer is the key to competitiveness. Speed is becoming an increasingly important differentiating factor.”
Therefore, this biotechnology center will be more than just a research facility; it will be a hub of innovation that can dramatically shorten the time from product development to market launch through collaboration with customers, business partners, biosolutions, and other business units.
You must be logged in to post a comment.